Report on the international symposium on osteoporosis

1. Клинические рекомендации «Остеопороз». Доступно по: https://cr.minzdrav.gov.ru/recomend/87_4

2. Cummings S, Martin J, McClung M, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine. 2009;361(8):756-765. doi: https://doi.org/10.1056/nejmoa0809493

3. Boonen S, Adachi JD, Man Z, et al. Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk. J Clin Endocrinol Metab. 2011;96(6):1727-1736. doi: https://doi.org/10.1210/jc.2010-2784

4. Bone H, Brandi M, Brown J, et al. OP0306 Ten Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results from The Freedom Extension Trial. Ann Rheum Dis. 2016;75(Suppl 2):173.2-174. doi: https://doi.org/10.1136/annrheumdis-2016-eular.1314

5. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi: https://doi.org/10.1210/jc.2019-002217

6. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020;26(3):1-46. doi: https://doi.org/10.4158/GL-2020-0524SUPPL

7. Kim SC, Kim MS, Sanfélix-Gimeno G, et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med. 2015;128(5):519-26.e1. doi: https://doi.org/10.1016/j.amjmed.2015.01.014

8. Seebeck J, Goldhahn J, Städele H, et al. Effect of cortical thickness and cancellous bone density on the holding strength of internal fixator screws. J Orthop Res. 2004;22(6):1237-42. doi: https://doi.org/10.1016/j.orthres.2004.04.001

9. Клинические рекомендации МЗ РФ «Патологические переломы, осложняющие остеопороз». Доступно по: https://www.cito-priorov.ru/cito/files/%D0%9F%D0%B0%D1%82%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D0%BF%D0%B5%D1%80%D0%B5%D0%BB%D0%BE%D0%BC%D1%8B_%D0%BE%D1%81%D0%BB_%D0%BE%D1%81%D1%82%D0%B5%D0%BE%D0%BF%D0%BE%D1%80%D0%BE%D0%B7.pdf

10. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94 (23):2113-9. doi: https://doi.org/10.2106/JBJS.K.00774

11. Atmaca A, Demirci I, Haymana C, et al. No association of antiosteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. Osteoporos Int. 2021;17:1–10. doi: https://doi.org/10.1007/s00198-021-06067-2

12. Huang CF, Shiao MS, Mao TY. Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. Patient Prefer Adherence. 2021;15:1579-1584. doi: https://doi.org/10.2147/PPA.S316144

13. Tsourdi E, Yu EW, Jan de Beur SM, Drake MT. Vaccination for Coronavirus Disease 2019 (COVID‐19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches. J Bone Miner Res. 2021;36(6):1042-1047. doi: https://doi.org/10.1002/jbmr.4304